tradingkey.logo
搜索

Impact Biomedical Inc

IBO
添加自选
0.472USD
+0.003+0.68%
收盘 07/02, 13:00美东报价延迟15分钟
50.89M总市值
亏损市盈率 TTM

关于 Impact Biomedical Inc 公司

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc简介

公司代码IBO
公司名称Impact Biomedical Inc
上市日期Sep 16, 2024
CEOHeuszel (Frank D)
员工数量2
证券类型Ordinary Share
年结日Sep 16
公司地址1400 Broadfield Blvd.
城市HOUSTON
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编77084
电话15852321500
网址https://www.impactbiomedinc.com/
公司代码IBO
上市日期Sep 16, 2024
CEOHeuszel (Frank D)

Impact Biomedical Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%

常见问题

Impact Biomedical Inc的前五大股东是谁?

Impact Biomedical Inc 的前五大股东如下:Mr. Mark Suseck

有多少机构持有Impact Biomedical Inc(IBO)的股份?

截至2026Q1,共有37家机构持有Impact Biomedical Inc的股份,合计持有的股份价值约为2.77M,占公司总股份的2.56%。与2025Q4相比,机构持股有所增加,增幅为2084658.00。